(Q39943797)

15 September 2017

title

Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study (English)

1 reference

secondary hyperparathyroidism

15 September 2017

1 reference

1 reference

Neal Mittman

1

1 reference

15 September 2017

Brinda Desiraju

2

1 reference

15 September 2017

Kevin B Meyer

3

1 reference

15 September 2017

Jyoti Chattopadhyay

4

1 reference

15 September 2017

Morrell M Avram

5

1 reference

15 September 2017

publication date

1 August 2010

1 reference

Kidney International. Supplement

15 September 2017

published in

1 reference

15 September 2017

issue

117

1 reference

15 September 2017

page(s)

S33-6

1 reference

Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Consequences and management of hyperphosphatemia in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Vitamin D analogs: therapeutic applications and mechanisms for selectivity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Are new vitamin D analogues in renal bone disease superior to calcitriol?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Vitamin D analogs for the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Derangement of glucose metabolism in hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Renal osteodystrophy: pathogenesis and management

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Studies on bone markers and bone mineral density in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.191

7 January 2021

Identifiers

DOI

10.1038/KI.2010.191

1 reference

15 September 2017

1 reference